Understanding why GPs see pharmaceutical reprensentatives: A qualitative interview study

British Journal of General Practice

Volumn 53, Issue 489, 2003, Pages 305-311

  Prosser, Helen ^a   Walley, Tom ^a  

^a Prescribing Research Group   (United Kingdom)

Author keywords

Bias; Evidence; Information; Pharmaceutical representatives; Prescribing; Quality

Indexed keywords

ARTICLE; CONSULTATION; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; GENERAL PRACTICE; GENERAL PRACTITIONER; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; INTERVIEW; MEDICAL INFORMATION; OUTCOMES RESEARCH; PARAMEDICAL PERSONNEL; PHARMACY; QUALITATIVE ANALYSIS; UNITED KINGDOM;

DRUG INDUSTRY; ENGLAND; HUMANS; INFORMATION DISSEMINATION; INTERDISCIPLINARY COMMUNICATION; MOTIVATION; PHYSICIANS, FAMILY; PROFESSIONAL COMPETENCE;

EID: 0037393659     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Prescribing new drugs in general practice. MeReC Bulletin 1998; 9(6): 21-24.
2. McGettigan P, Golden J, Fryer J, et al. Prescribers prefer people: The sources of information used by doctors for prescribing suggest that the medium is more important than the message. Br J Clin Pharmacol 2000; 51: 184-189.
3. Lexchin J. Doctors and detailers: Therapeutic education or pharmaceutical promotion? Int J Health Serv 1989; 19(4): 663-669.
4. Zeigler M, Lew P, Singer B. The accuracy of drug information from pharmaceutical sales representatives. JAMA 1995; 273: 1296-1298.
5. Lexchin J. What information do physicians receive from pharmaceutical representatives? Can Fam Physician 1997; 43: 941-945.
6. Hodges B. Interactions with the pharmaceutical industry: Experiences and attitudes of psychiatry residents, interns and clerks. CMAJ 1995; 153: 553-559.
7. Peay MY, Peay ER. The role of commercial sources in the adoption of a new drug. Soc Sci Med 1998; 26: 1183-1189.
8. Wazana A. Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA 2000; 283: 391-393.
9. Prosser H, Almond S, Walley T. Influences of GPs' decision to prescribe new drugs - The importance of who says what. Fam Pract 2003; 20: 61-68.
10. Griffith D. Reasons for not seeing drug representatives. BMJ 1999; 319: 69-70.
11. Reasons for not seeing drug representatives. [Electronic responses.] eBMJ 1999; 319. URL: www.bmj.com/cgi/content/full/319/7202/69
12. Somerset M, Weiss M, Fahey T. Dramaturgical study of meetings between general practitioners and representatives of pharmaceutical companies. BMJ 2001; 323: 1481-1484.
13. Glaser B, Strauss A. The Discovery of Grounded Theory. Chicago: Aldine, 1967.
14. Roughead EE, Harvey KJ, Gilbert AL. Commercial detailing techniques used by pharmaceutical representatives to influence their prescribing. Aust NZ J Med 1998; 28: 306-310.
15. Fill C. Marketing Communications: Contexts, Contents and Strategies. London: Prentice Hall, 1999.
16. Slawson DC, Shaughnessey AF. Teaching information mastery: Creating informed consumers of medical information. J Am Board Fam Pract 1999; 12: 444-449.
17. Anastasio GD, Little JM. Pharmaceutical marketing: Implications for medical residency training. Pharmacotherapy 1996; 16: 103-107.